Clinical Trial Update: Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) [Phase 2]

View source ↗

Summary

Phase 2 immunogenicity study of a recombinant HPV vaccine targeting multiple HPV types has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Condylomata Acuminata

Drugs mentioned

• Recombinant Human Papillomavirus Vaccine (types 6,11,16,18,31,33,45,52,58) (E. coli expression)

Snippet

Sponsor: Xiamen University | Conditions: Condylomata Acuminata, Cervical Cancer | Phase 2 | Status: COMPLETED